Changing the Face of Oral Cancer Testing
Changing the Face of Oral Cancer Testing
Cancer testing remains the most important lever for reducing oncology patient burden, find it early, treat it earlier.
Existing cancer testing can be difficult to access due to high cost, ineffective delivery, and uncertain reimbursement or funding.
For oral cancer existing tools are either incapable, inaccurate human inspection, or don’t incentivize adoption and utilization through high cost to dental providers.
Wisdom Bioscience's approach will enable the broad adoption of gold-standard molecular testing for oral cancer, with little or no cost to Dentists or Patients.
A diiferentiated, IP protected, approach that utilizes existing biomarkers and technology. The company is led by an experienced team, each with more than 25 years of healthcare, laboratory operations, and molecular diagnostic development.

Our team of experienced scientists has developed a state-of-the-art test to provide an early indication of elevated risk of this disease.

Wisdom Bioscience offers a state-of-the-art oral cancer test that can detect early signs of this devastating disease. Our advanced diagnostic technology provides accurate and reliable results.

25 years’ clinical diagnostics industry experience including public and private markets, specializing in molecular diagnostics, including:

Experienced scientific leader, with more than 15 years of expertise in molecular biology, assay and technology development.
Scientist, Genentech
Staff Scientist, Q2 Solutions

Vern has four decades counseling innovative life sciences companies and working closely with them to develop successful business and IP strategies. In his legal practice, he has represented a wide variety of companies, as well as venture capital firms, in areas such as therapeutics, diagnostics, nanotechnology, genomics, proteomics, and p
Vern has four decades counseling innovative life sciences companies and working closely with them to develop successful business and IP strategies. In his legal practice, he has represented a wide variety of companies, as well as venture capital firms, in areas such as therapeutics, diagnostics, nanotechnology, genomics, proteomics, and personalized medicine. He has also served as a founder, and business counselor to a range of life science companies, including Affymetrix, which he took public ($10B IPO). Vern is recognized among the country's top life sciences attorneys in Chambers USA: America's Leading Lawyers for Business. A fun fact about Vern: his interest in the field of personalized medicine prompted him to become the first attorney to have had his/her entire genome sequenced and made available in a public database. He have served on a number of boards of academic institutions and life science institutions in neurology, oncology, and related human and animal health organizations. In academics, he has served as an adjunct professor in biotechnology for over 14 years.

Executive Chairman of Wisdom Biosciences

Professor Scott E. Fraser has a long-standing commitment to quantitative biology, applying the tools of chemistry, engineering, and physics to problems in fields ranging from developmental biology to medicine.
He has served on the faculties of UC Irvine, Caltech & USC, and now is the Vice President of the CZI, one of the largest science philanthropies.

Giulia Kennedy Ph.D.
Arnold Levine Ph.D.
John Sninisky Ph.D.
Marty Goldberg Ph.D.
Prof. Ian Weeks
Prof Tin Tin Su
Jake Sylwanowicz DDS
Christine Nam DDS
Howard B Short DMD